Zynerba Pharmaceuticals Company Profile (NASDAQ:ZYNE)

Analyst Ratings

Consensus Ratings for Zynerba Pharmaceuticals (NASDAQ:ZYNE) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.60 (347.80% upside)

Analysts' Ratings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Show:
DateFirmActionRatingPrice TargetActions
7/26/2016Piper Jaffray Cos.Reiterated RatingOverweight$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/18/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016Jefferies GroupReiterated RatingBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2016Roth CapitalInitiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/12/2016        
5/12/2016Q1($0.56)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q415($0.29)($0.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2015Q3($0.41)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.51)($0.43)($0.47)
Q2 20162($0.51)($0.48)($0.50)
Q3 20162($0.64)($0.56)($0.60)
Q4 20162($0.63)($0.54)($0.59)
Q1 20171($0.71)($0.71)($0.71)
Q2 20171($0.71)($0.71)($0.71)
Q3 20171($0.59)($0.59)($0.59)
Q4 20171($0.56)($0.56)($0.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
DateHeadline
07/23/16 08:31 AMAre Analysts Bullish Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) After Last Week? - Press Telegraph
07/22/16 10:23 AMEarnings Focus and Crowd Sourced Sentiment Review for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - TGP
07/22/16 10:23 AMCan Zynerba Pharmaceuticals Inc's Tomorrow Be Different? The Stock Increases Again - Consumer Eagle
07/20/16 08:36 PMTracking Analyst Ratings and Target Projections for: Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Press Telegraph
07/20/16 10:21 AMStock Moving Lower for the Month; Investor Update on Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Engelwood Daily
07/19/16 07:39 PMZynerba Pharmaceuticals Inc (NASDAQ:ZYNE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/18/16 04:17 AMTrading Performance and Target Watch for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Press Telegraph
07/18/16 04:17 AMNext Weeks Broker Price Targets For Zynerba Pharmaceuticals, Inc. (ZYNE) - Fiscal Standard
07/16/16 10:36 AMHow Analysts Rated Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Last Week? - Consumer Eagle
07/14/16 07:42 PMAnalyst Target and Average Rating Watch: Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Press Telegraph
07/14/16 07:42 PMCrowd Rating and Earnings Recap for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Telanagana Press
07/12/16 07:42 PMZynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/08/16 07:22 PMZynerba Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - Yahoo Finance
07/07/16 10:07 AMIncreased Volatility Watch for: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Engelwood Daily
07/07/16 10:07 AMZynerba Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - Nasdaq
07/06/16 06:31 AMZynerba Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [at noodls] - DEVON, Pa., July 06, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic ...
07/05/16 07:01 PMForm 8-K Zynerba Pharmaceuticals, For: Jul 05
07/04/16 04:13 AMCompany Stock Lower on the Week Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Engelwood Daily
06/29/16 07:22 PMBrokers Issue Average Price Target Of 33.60 On Zynerba Pharmaceuticals, Inc. (ZYNE) - Fiscal Standard
06/29/16 10:07 AMZynerba Pharma (ZYNE) Reports Positive Top Line Results from ZYN002 CBD Gel Phase 1, Plans Phase 2 Study
06/28/16 07:25 PMZynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 07:25 PMShare Update and Earnings Review for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Press Telegraph
06/28/16 05:02 AMZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
06/28/16 04:16 AMStock Volatility in Review: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Engelwood Daily
06/28/16 04:16 AMEquity Research and Technical Review on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Press Telegraph
06/27/16 03:31 PMZynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures - [at noodls] - DEVON, Pa., June 27, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid ...
06/27/16 08:00 AM15 Stocks Moving In Monday's Pre-Market Session - Gainers HeartWare International Inc (NASDAQ: HTWR) rose 91.49 percent to $57.41 in pre-market trading after Medtronic PLC (NYSE: MDT) announced its plans to acquire HeartWare for $58 per share in cash. GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares rose 17.96 percent to $98.27 in pre-market trading following positive Epidiolex results. The company reported that Epidiolex met the primary endpoint in Phase 3 trial. Great Lakes Dredge & Dock Corporation (NASDAQ: GLDD) shares rose 13.56 percent to $5.11 in pre-market trading after dropping 5.46 percent on Friday. Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares rose 9.15 percent to $8.35 in pre-market trading after falling 1.54 percent on Friday. Energy Transfer Equity LP (NYSE: ETE) rose 5.78 percent to $14.63 in pre-market trading after a Delaware judge decided the company could walk away from its $20 billion+ takeover of Williams Companies without a penalty. Skullcandy Inc (NASDAQ: SKUL) shares rose 4.7 percent to ...Full story available on Benzinga.com
06/27/16 04:01 AMZynerba Pharmaceuticals, Inc. (ZYNE) Broker Price Targets For The Coming Week - Fiscal Standard
06/24/16 07:25 PMRecently Issued Stock Ratings For Zynerba Pharmaceuticals, Inc. (ZYNE) - Fiscal Standard
06/24/16 07:25 PMShare Volatility Check for: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Press Telegraph
06/23/16 08:17 PMFatty Acid Amide Hydrolase - Pipeline Review, H1 2016 - New Report Available
06/22/16 07:24 PMDoes oral cannabidiol convert to THC, a psychoactive form of cannabinoid, in the stomach?
06/22/16 04:04 AMNew study reveals conversion of oral cannabidiol to THC by acidic fluids in the stomach
06/20/16 06:53 PMThis Weeks Broker Views For Zynerba Pharmaceuticals, Inc. (ZYNE) - Fiscal Standard
06/15/16 07:17 PMZynerba Pharmaceuticals, Inc. (ZYNE) Current Analyst Ratings - Fiscal Standard
06/10/16 07:54 PMMarket of Rett Syndrome Pipeline Reviewed of 14 Companies and 23 Drug Profiles
06/09/16 10:37 AM"Fragile X Syndrome Global Clinical Trials Review, H1, 2016" is now available at Fast Market Research
06/04/16 10:40 AMAnalyst's Overview of Two Stocks: ABIOMED, Inc. (NASDAQ:ABMD) , Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Street Updates
06/03/16 06:16 PMWeeding Out the Winners in Race for Cannabis-Based Drugs -
06/03/16 10:35 AMForm 8-K Zynerba Pharmaceuticals, For: May 25
06/02/16 10:50 AMBroker Watchlist: Zynerba Pharmaceuticals, Inc. (ZYNE) - Share Trading News - Broker Watchlist: Zynerba Pharmaceuticals, Inc. (ZYNE)Share Trading News11/12/2015 – Zynerba Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 35 price target on the stock. The share price of Zynerba Pharmaceuticals, Inc. (ZYNE) was up +1.14% during the last trading ...and more »
06/01/16 10:33 AMZynerba Pharmaceuticals Inc (NASDAQ:ZYNE)'s Company Shares Decreased 4.91% After High Volatility - HNN - Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)'s Company Shares Decreased 4.91% After High VolatilityHNNThe shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) decreased by 4.91% in the last 20 days but rose 7.04% in the past 5 trading sessions. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) shares opened at $7.64 in the last session and had intraday ...
06/01/16 06:23 AMZynerba Pharmaceuticals to Participate in Upcoming Investor Meetings and Conferences - [at noodls] - DEVON, Pa., June 01, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid ...
05/31/16 07:55 AMStock Review and Earnings Check on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - HNN - Stock Review and Earnings Check on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Zynerba Pharmaceuticals Inc ...and more »
05/30/16 08:52 PMTarget Check and Stock Performance Recap Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - HNN - Target Check and Stock Performance Recap Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)HNNTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Zynerba Pharmaceuticals Inc ...and more »
05/28/16 01:41 PMGlobal Peripheral Neuropathic Pain Therapeutics Pipeline Report 2016 - 10 Companies & Drug Profiles - Research and Markets - ... and Company GW Pharmaceuticals Plc Nektar Therapeutics Phosphagenics Limited Spherium Biomed S.L. Sunovion Pharmaceuticals Inc. Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/bfhjwd/peripheral View ...
05/24/16 12:04 PMTarget Check and Stock Performance Recap Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Wall Street Hints and News - Target Check and Stock Performance Recap Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Zynerba Pharmaceuticals Inc ...and more »
05/24/16 12:04 PMEarnings Review and Stock Rundown for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Wall Street Hints and News - Earnings Review and Stock Rundown for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) ...and more »
05/22/16 12:18 PMZynerba Pharmaceuticals Incorporated (NASDAQ:ZYNE) Shorted Shares Increased By 19.33% - Wall Street Hints and News - Zynerba Pharmaceuticals Incorporated (NASDAQ:ZYNE) Shorted Shares Increased By 19.33%Wall Street Hints and NewsZynerba Pharmaceuticals, Inc. is a specialty pharmaceutical firm focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The company has a market cap of $64.55 million. The Firm is evaluating ...and more »
05/21/16 12:45 PMStocks to Watch: VWR Corporation (NASDAQ:VWR), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Cabela's ... - KC Register - Stocks to Watch: VWR Corporation (NASDAQ:VWR), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Cabela's ...KC RegisterZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) reported financial results for the quarter ended March 31, 2016. As of March 31, 2016, cash and cash equivalents were $36.8 million, compared to $41.5 million as of December 31, 2015. Research and ...

Social

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals logoZynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain. The Company's ZYN002 is the synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear, odorless gel that is designed to provide controlled drug delivery with once- or twice-daily dosing. The Company's ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The transdermal patch is a non-invasive and non-oral dosage form of method of delivery. ZYN001 is a pro-drug, which is a drug administered in an inactive or less active form.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ZYNE
  • CUSIP:
Key Metrics:
  • Previous Close: $7.18
  • 50 Day Moving Average: $7.67
  • 200 Day Moving Average: $8.09
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $64.85M
  • Current Year EPS Consensus Estimate: $-2.37 EPS
  • Next Year EPS Consensus Estimate: $-2.46 EPS
Additional Links:
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Chart for Tuesday, July, 26, 2016